Related Experiment Video
Updated: Jul 19, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Euglycemic hyperinsulinemia in severe sepsis and septic shock
Fuhong Su1, Zhen Wang, Alejandro Bruhn
1Department of Intensive Care, Erasme Hospital, Free University of Brussels, Brussels, Belgium.
Summary
Euglycemic hyperinsulinemia (EH) in a sheep model of septic shock did not improve survival or hemodynamics. While EH reduced interleukin-6 levels, it did not offer significant clinical benefits in this study.
Area of Science:
- Critical Care Medicine
- Sepsis Research
- Metabolic Studies
Background:
- Intensive insulin therapy may improve outcomes in critically ill patients.
- The effects of strict glucose control in septic shock remain unclear.
- Distinguishing benefits of insulin per se versus glucose control is challenging.
Purpose of the Study:
- To investigate the hypothesis that euglycemic hyperinsulinemia (EH) improves outcomes in a sheep model of septic shock.
- To assess the impact of EH on hemodynamics, interleukin-6 levels, and survival time.
- To determine if insulin administration itself, or glucose control, drives potential benefits.
Main Methods:
- A sheep model of septic shock was induced using intraperitoneal feces injection.
- Animals were randomized to either EH (insulin infusion, glucose, potassium control) or a control group.
- Hemodynamic variables, blood glucose, potassium, and interleukin-6 levels were monitored over 30 hours.
Main Results:
- Euglycemic hyperinsulinemia (EH) did not significantly alter hemodynamic variables compared to controls.
- Interleukin-6 levels tended to be lower in the EH group, suggesting an anti-inflammatory effect (p < 0.05).
- Survival times were similar between the EH and control groups (median 20.0h vs. 17.0h, p = 0.73).
Conclusions:
- In this septic shock model, euglycemic hyperinsulinemia (EH) reduced interleukin-6 concentrations.
- EH did not demonstrate improvements in hemodynamic parameters or overall survival.
- The findings suggest EH may not be a beneficial intervention for septic shock in this model.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:21Hyperosmolar Hyperglycemic State
Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...